Lawrence Hineline - Intra Cellular Insider

ITCI -- USA Stock  

USD 18.46  0.19  1.02%

Vice President and CFO

Mr. Lawrence J. Hineline, CPA, is Chief Financial Officer, Vice President Finance, Treasurer, Assistant Secretary of IntraCellular Therapies, Inc. Mr. Hineline also served as the Secretary of the Company from August 2013 until September 2014. From December 2000 to November 2003, Mr. Hineline was the Vice President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporationrationrate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a startup and was later acquired by Baxter Health Care
Age: 59  President Since 2014  CPA    
Hineline is a licensed CPA in the State of Maryland and received his Bachelor?s Degree from the University of Maryland Baltimore County.

Lawrence Hineline Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (17.14) % which means that it has lost $17.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.39) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.

Intra Cellular Thera Leadership Team

Lawrence Wennogle, President, Ph.D
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Director
Richard Lerner, Director
Robert Davis, President, Ph.D
Allen Fienberg, Founder, Ph.D
Michael Halstead, SVP
Sharon Mates, Chairman, Ph.D
Andrew Satlin, President
Juan Sanchez, President
Rory Riggs, Director, MBA
Joel Marcus, Director
Kimberly Vanover, VP, Ph.D
Lawrence Hineline, President, CPA

Stock Performance Indicators

Current Sentiment - ITCI

Intra Cellular Thera Investor Sentiment
Most of Macroaxis users are currently bullish on Intra Cellular Therapies. What is your judgment towards investing in Intra Cellular Therapies? Are you bullish or bearish?
98% Bullish
2% Bearish

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.